. The intensity of neovasculan'sation reflects tumour cell angiogenic activity (Blood and Zetter, 1990; Folkman, 1990). Microvessel density has been shown to be a prognostic predictor in patients with lung cancer (Macchiarini et al., 1992) , prostatic cancer (Weidner et al., 1993) and malignant melanoma (Srivasta et al., 1988) . With regard to breast cancer, Weidner et al. (1991) found a significant correlation between microvessel density and the presence of metastatic disease. They also reported a relationship between microvessel count (MVC) and prognosis (Weidner et al.. 1992) . Since mortality in breast cancer is related to the occurrence of distant metastasis, the histological quantitation of intra-tumour microvessels may predict prognosis in some subsets of breast cancer patients and provide useful information for deciding therapeutic strategies.
Axillary lymph node status has been considered the most important prognostic factor in breast cancer, although it does not fully account for the varied prognosis associated with this disease. Approximately 20-30% of lymph node-negative breast cancer patients will develop recurrent disease with consequent risk of death within 10 years of the initial local therapy (McGuire, 1989; Singurdsson et al., 1990; Osborne, 1992) . Thus, new, reliable prognostic indicators that could identify patients at high nrsk for recurrence and death could prove useful in guiding treatment and decreasing mortality.
Growth and metastasis of cancer cells require several processes, with angiogenesis playing a key role (Blood and Zetter, 1990; Bicknell and Harris, 1991; Hart and Saini, 1992) . The intensity of neovasculan'sation reflects tumour cell angiogenic activity (Blood and Zetter, 1990; Folkman, 1990) . Microvessel density has been shown to be a prognostic predictor in patients with lung cancer (Macchiarini et al., 1992) , prostatic cancer (Weidner et al., 1993) and malignant melanoma (Srivasta et al., 1988) . With regard to breast cancer, Weidner et al. (1991) found a significant correlation between microvessel density and the presence of metastatic disease. They also reported a relationship between microvessel count (MVC) and prognosis (Weidner et al.. 1992) . Since mortality in breast cancer is related to the occurrence of distant metastasis, the histological quantitation of intra-tumour microvessels may predict prognosis in some subsets of breast cancer patients and provide useful information for deciding therapeutic strategies.
The purpose of this study was to examine the correlation between tumour (MVCs) and clinicopathological factors, and to determine whether microvessel quantitation could identify breast cancer patients at high risk for recurrence and death. using immunohistochemical staining of formalin-fixed, paraffin-embedded sections for factor VIII-related antigen. 
Materials and metbods

Patients
Microvessel quantitation
Microvessel quantitation was performed by light microscopy by observers without knowledge of patients data. First, the area of highest microvascular density of the tumour was found by scanning at 40 x magnification, and then the single field with the highest number of microvessels at 200 x magnification (0.785 mm2 per field) was identified. Any brown-stained endothelial cell that had clearly separated from adjacent microvessels, tumour cells and other connective tissue elements was considered to be a single countable microvessel. Undefined endothelial cells which appeared to be fragments were not counted as microvessels. The presence of a vessel lumen was not required to classify a structure as a vessel. For each tumour, the MVC was asd independently by three investigators. The average of these three counts was taken as the MVC of the tumour. Figure 1 (Table H) . Stratification by stage showed signiiant differences in MVC between relapsing with distant metastasis and disease-free patients for each stage group in a 10-year period (Figure 2 ).
MVC and survival
The mean MVC of all 155 patients, which was 52.8, was used as-a cut-off point between high-and low-MVC groups. There was no significant difference in the distribution of clinicopathological factors between the two groups ( Table I ).
The prognosis of high-MVC patients was significantly poorer than that of low-MVC cases. Figure 3a shows a difference in relape-free survival rate between the high-MVC and low-MVC groups (P<0.025). Figure 3b shows a difference in overall survival rate between the two groups (P< 0.01). Stratification by nodal status showed that MVC was related to the relapse-free survival rate in lymph nodenegative patients (P<0.01), but not in lymph node-positive patients (Figure 4 ). In addition, MVC was related to the overall survival rate both in lymph node-negative and lymph node-positive patients (P<0.01 and P<0.025 respectively) ( Figure 5 (Blood and Zetter, 1990; Bicknell and Harris, 1991; Hart and Saini, 1992) . Without the ability to recruit new vessels, most tumours would remain localised to their primary site (Liotta et al., 1974 Tumour growth is also dependent on angiogenesis. Tumours cannot expand beyond 1-2 mml without sufficient neovascularisation but can expand rapidly to 1-2 cm3 after vasculaisation (Folk-man et al., 1966; Sutherland et al., 1971 (Blood and Zetter, 1990; Foliman, 1994 Several studies (Bosari et al., 1992; Horak et al., 1992; Weidner et al., 1992; Toi et al., 1993) (Gould et al., 1983) . In our study, MVC was not related to tumour histological grade. However, Jensen et al. (1982) (Bosari et al., 1992; Horak et al., 1992; Weidner et al., 1992; Toi et al., 1993; Gasparini et al., 1994) have reported the significance of MVC as a prognostic predictor. Our results demonstrate a significant difference in relapse-free survival and overall survival rates between high-and low-MVC groups. Differences in both relapse-free survival and overall survival were also seen in lymph node-negative patients in different MVC groups, as well as differences in overall survival in lymph node-positive patients. Tumour metastasis occurs via both the blood circulation and lymphatic system; however, mortality in breast cancer is due mainly to the former. The significance of MVC as a prognostic indicator for death might best be demonstrated by multivanrate analysis.
Microvessel quantitation may be used as an indicator of the existence of occult systemic metastasis in breast cancer patients with no clinical evidence of metastatic disease as well as a predictor of death in breast cancer patients. Such information could prove useful for deciding on the need for adjuvant therapy so as to reduce morbidity and motality from breast cancer.
